Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanesColin F. Spraggs, Martine Piccart, Laura R. Parham et al.|The Pharmacogenomics Journal|2017Cited by 22
MO802: Genetics Plays a Limited Role in ESA-Hyporesponsiveness and Haemoglobin Outcomes in End-Stage Renal Disease Patients on HaemodialysisSivakumar Gowrisankar, Rubeen Israni, Gilbert Marlowe et al.|Nephrology Dialysis Transplantation|2022Cited by 0